Acute graft versus host disease affecting the skin is one of the most common complications after receiving stem cells from a donor, appearing in up to 60% of transplant recipients and often serving as the first visible sign that the donor’s immune system is reacting against the recipient’s body.

Understanding Treatment Goals for Skin GVHD After Transplant

When someone receives stem cells or bone marrow from another person to treat serious blood diseases or cancers, their body essentially receives a new immune system. This life-saving procedure can sometimes lead to a condition where the donated immune cells see the recipient’s skin and other tissues as foreign invaders and begin attacking them. This reaction, known as acute graft versus host disease or acute GVHD, most commonly shows up on the skin within the first 100 days after transplant, though it can appear later as well.^[1]

The primary goal of treating acute skin GVHD is to calm down the overactive immune response while preserving the beneficial effects of the transplant. Doctors aim to control symptoms like rashes, itching, and pain, prevent the condition from worsening or spreading to other organs, and help patients maintain their quality of life during recovery. Treatment decisions depend heavily on how severe the skin involvement is, which parts of the body are affected, and how each individual patient responds to therapy.^[2]

Medical professionals now have access to both time-tested treatments that have been used for decades and newer therapeutic options being studied in clinical trials. The treatment landscape has evolved significantly, with researchers constantly working to find therapies that are more effective and cause fewer side effects. Some patients need only simple skin creams, while others require powerful medications given through the bloodstream to control widespread disease.^[1]

Because skin is usually the first organ affected by GVHD, dermatologists and transplant specialists play a crucial role in catching the disease early. Quick recognition and prompt treatment can make a substantial difference in outcomes. The medical team carefully monitors each patient, adjusting treatments as needed based on how the skin responds and whether other organs become involved.^[9]

Standard Treatment Approaches for Acute Skin GVHD

The cornerstone of treating acute graft versus host disease of the skin has long been medications called corticosteroids, commonly known as steroids. These powerful drugs work by suppressing the immune system’s inflammatory response that causes the donor cells to attack the recipient’s skin. For mild cases affecting small areas of skin, doctors often start with topical steroid creams applied directly to the rash, such as triamcinolone 0.1%. This approach allows treatment of the affected area without exposing the entire body to medication.^[10]

When skin GVHD becomes more widespread or severe, patients typically need systemic steroids, meaning medication that travels throughout the body. The most commonly prescribed systemic steroid is methylprednisolone, usually started at a dose of 2 milligrams per kilogram of body weight per day, given in two divided doses. Patients generally continue taking their original transplant medications, such as cyclosporine or tacrolimus, while adding the steroid treatment. The median time for acute GVHD to resolve with this treatment is typically 30 to 42 days.^[11]

Cyclosporine and tacrolimus are medications called calcineurin inhibitors, which work by blocking specific signals that activate immune cells. These drugs are often given as preventive therapy starting right after transplant to reduce the risk of GVHD developing in the first place. When used as part of preventive treatment, cyclosporine levels in the blood are kept above 200 nanograms per milliliter. Tacrolimus is frequently chosen over cyclosporine, especially when the stem cell donor is unrelated to the patient, because it may provide better control of GVHD, though it doesn’t necessarily improve overall survival rates.^[11]

Another medication sometimes used in standard treatment is mycophenolate mofetil, abbreviated as MMF. This drug suppresses immune function by interfering with the production of new immune cells. Some transplant centers use MMF as part of the initial prevention strategy, often in combination with tacrolimus, to reduce the likelihood of GVHD developing. When GVHD does occur despite preventive efforts, MMF may be added to the treatment regimen.^[11]

A specialized light therapy called extracorporeal photopheresis, or ECP, represents another established treatment option. During this procedure, doctors collect a patient’s white blood cells through a process similar to dialysis. The collected cells are mixed with a light-sensitive medication called 8-methoxypsoralen, then exposed to ultraviolet light before being returned to the patient’s bloodstream. This process makes the immune cells more likely to die off naturally, reducing the immune attack on the skin. ECP has been used both to prevent GVHD as part of pre-transplant conditioning and to treat GVHD that has already developed.^[11]

Standard treatments also include supportive care measures that help manage symptoms and prevent complications. Patients are advised to keep their skin well moisturized with fragrance-free creams, use gentle soaps, avoid extreme temperatures, and protect their skin from sun exposure. These measures, while seemingly simple, play an important role in patient comfort and can help reduce the severity of symptoms. Cotton clothing is recommended over synthetic fabrics, and patients should avoid rubbing their skin dry, instead patting gently or allowing skin to air dry.^[10]

The duration of treatment varies considerably depending on how quickly and completely the skin GVHD responds. Some patients improve within weeks and can gradually reduce their medications, while others require months of treatment. Throughout this time, doctors monitor patients closely with physical examinations and sometimes skin biopsies to assess treatment response and watch for complications. Blood tests help track liver function, blood sugar levels, and signs of infection that can occur as side effects of immune-suppressing medications.^[1]

Side effects from standard treatments can be significant. Steroids, while effective, may cause increased appetite and weight gain, fluid retention, elevated blood pressure, mood swings, difficulty sleeping, increased susceptibility to infections, elevated blood sugar, and gradual weakening of bones. Cyclosporine and tacrolimus can affect kidney function, raise blood pressure, cause tremors, and increase the risk of infections. Because of these potential complications, the medical team carefully balances the benefits of controlling GVHD against the risks of treatment side effects.^[3]

When Standard Treatment Doesn’t Work: Steroid-Refractory GVHD

Unfortunately, not all patients respond adequately to first-line steroid therapy. When skin GVHD fails to improve or continues to worsen despite treatment with steroids, doctors describe this as steroid-refractory disease. This situation presents a significant challenge because no single second-line therapy has proven clearly superior to others in controlled studies. Different medical centers may favor different approaches based on their experience and the individual patient’s circumstances.^[1]

Several medications have shown promise for steroid-refractory skin GVHD. Sirolimus is an immune-suppressing drug that works differently from calcineurin inhibitors, blocking a protein called mTOR that immune cells need to multiply. Some transplant centers add sirolimus when steroids aren’t controlling GVHD adequately. Similarly, additional immunosuppressive agents may be tried, often in combination with the patient’s existing medication regimen.^[11]

Biological therapies targeting specific immune system components have also been explored. Antithymocyte globulin, or ATG, contains antibodies that destroy T lymphocytes, the immune cells primarily responsible for attacking the recipient’s tissues in GVHD. While ATG is sometimes used as preventive therapy before transplant or to treat GVHD that develops, it significantly reduces the immune system’s ability to fight infections, which must be carefully considered.^[11]

Another approach involves medications that block specific inflammatory signals. Anti-interleukin-2 receptor antibodies target a protein on activated immune cells, helping to shut down the immune attack without completely eliminating all immune function. These targeted therapies aim to be more selective than broad immune suppression, potentially reducing side effects while maintaining effectiveness.^[11]

Promising Treatments Being Studied in Clinical Trials

The field of GVHD treatment is rapidly evolving, with numerous innovative therapies being tested in clinical trials around the world. These studies are conducted in phases to systematically evaluate new treatments. Phase I trials focus primarily on safety, determining appropriate doses and identifying potential side effects in small groups of patients. Phase II trials expand to larger groups to assess whether the treatment actually works in reducing GVHD symptoms and how effective it is. Phase III trials compare the new treatment directly against current standard therapies to determine if it offers meaningful advantages.^[8]

One class of drugs showing considerable promise consists of Janus kinase inhibitors, also called JAK inhibitors. These medications block enzymes called Janus kinases that transmit inflammatory signals inside cells. Ruxolitinib is a JAK inhibitor that has been studied extensively for both acute and chronic GVHD affecting the skin. By interfering with multiple inflammatory pathways simultaneously, ruxolitinib can dampen the immune response without completely shutting down the immune system. Clinical trials have shown positive safety profiles and improvements in skin symptoms for some patients who didn’t respond well to steroids.^[13]

Another JAK inhibitor called ibrutinib, marketed as Imbruvica, was originally developed to treat certain blood cancers but has shown activity against chronic GVHD. While more commonly used for the scarring type of chronic skin GVHD that develops later after transplant, research into its potential role in acute GVHD continues. These drugs work by blocking the Bruton’s tyrosine kinase enzyme, which plays a role in immune cell activation.^[13]

A medication called belumosudil, known by the brand name Rezurock, represents another targeted therapy being investigated. This drug inhibits an enzyme called Rho-associated coiled-coil kinase 2, or ROCK2, which is involved in the inflammatory processes underlying GVHD. By blocking ROCK2, belumosudil affects multiple pathways that contribute to tissue damage in GVHD. Clinical trials have evaluated belumosudil primarily for chronic GVHD, including skin involvement, with several studies conducted in the United States and Europe.^[13]

Axatilimab, sold as Niktimvo, is a newer therapeutic approach currently in clinical trials. This is a monoclonal antibody, meaning it’s a laboratory-made protein designed to target a specific molecule. Axatilimab blocks the colony-stimulating factor-1 receptor, or CSF-1R, which is found on certain immune cells called macrophages that contribute to GVHD. By preventing CSF-1R from functioning, axatilimab reduces the activity of these inflammatory cells. Studies have shown encouraging results in patients with chronic GVHD affecting the skin who hadn’t responded to multiple other treatments.^[13]

Cell-based therapies represent an innovative frontier in GVHD treatment research. Mesenchymal stem cells, or MSCs, are special cells that can help regulate immune responses and promote tissue healing. Unlike the stem cells used in the original transplant, mesenchymal stem cells don’t create new blood cells but instead help modulate inflammation. Clinical trials have tested giving patients infusions of MSCs, either from donors or grown in laboratory cultures, to treat steroid-refractory GVHD. Early results have shown promise in some studies, with improvements in skin symptoms and acceptable safety profiles, though more research is needed to establish their role in standard care.^[11]

Researchers are also investigating antibody therapies that selectively remove or inactivate specific types of immune cells. Rituximab is a monoclonal antibody that targets a protein called CD20 found on B lymphocytes, another type of immune cell. While B cells aren’t the primary culprits in acute GVHD (that role belongs to T cells), they can contribute to chronic forms and ongoing inflammation. Some clinical trials have explored rituximab’s potential in GVHD treatment, particularly for chronic manifestations, though its role in acute skin GVHD remains under investigation.^[10]

Other monoclonal antibodies being studied include those targeting the CD5 protein on T cells, often linked to immunotoxins that poison the cells they bind to. These highly targeted approaches aim to eliminate the aggressive donor T cells causing GVHD while sparing other immune cells needed to fight infections and prevent disease relapse. Clinical trials of these agents typically start with Phase I studies to determine safe dosing before expanding to larger efficacy studies.^[11]

Abatacept is another biological agent under investigation for GVHD prevention and treatment. This medication blocks a signal called CD28 that T cells need to become fully activated. By interfering with this activation process, abatacept can prevent T cells from launching an attack on the recipient’s tissues. Clinical trials have evaluated abatacept both as a preventive measure given around the time of transplant and as a treatment for GVHD that has already developed.^[11]

Novel approaches to delivering phototherapy are also being refined in clinical trials. Beyond extracorporeal photopheresis, researchers are studying PUVA therapy, which stands for Psoralen plus Ultraviolet A light. Patients take or apply psoralen, a light-sensitizing medication, then receive controlled exposure to UVA light. This treatment, already used for other skin conditions like psoriasis, is being evaluated specifically for GVHD of the skin in various trial settings.^[10]

Some trials are investigating medications that were originally developed for other conditions but show potential in GVHD. Pentostatin is a chemotherapy drug that depletes certain immune cells, and it has been studied both as part of conditioning regimens before transplant to prevent GVHD and as treatment for established disease. Alemtuzumab is an antibody that targets CD52, a protein found on many immune cells, causing widespread immune cell depletion. While effective at reducing GVHD risk, these potent therapies require careful consideration of infection risks and other complications.^[11]

Keratinocyte growth factor, or KGF, represents a different therapeutic strategy altogether. Rather than suppressing the immune system, KGF helps protect and repair the skin and other tissues that GVHD damages. By promoting tissue healing and integrity, KGF might reduce the severity of GVHD symptoms. Clinical trials have explored giving KGF before and after transplant to see if it can prevent or reduce GVHD development.^[11]

Preliminary results from many of these clinical trials have been encouraging. Some studies have reported improvements in the percentage of body surface area affected by rash, reductions in itching and pain scores, decreased need for steroid medications, and better quality of life measures. However, researchers emphasize that these are early findings, and longer-term studies with larger patient numbers are needed to fully understand each therapy’s benefits and risks. The process of moving from promising early results to approved treatments that doctors can use routinely takes years of careful study.^[8]

Clinical trials for GVHD are conducted at specialized transplant centers that have the expertise and infrastructure to safely administer experimental therapies and carefully monitor patients. Major academic medical centers in the United States, such as those in New York, Boston, Houston, and other cities, frequently participate in GVHD treatment studies. European centers in countries including Germany, Austria, the United Kingdom, and others also conduct important research. Patients interested in trial participation should ask their transplant team about available studies and whether they might qualify.^[1]

Most Common Treatment Methods

• Topical Corticosteroids
  • Steroid creams like triamcinolone 0.1% applied directly to affected skin areas for mild, localized GVHD
  • Allow treatment of rash without exposing entire body to medication
  • Often used for Stage I or II skin involvement
• Systemic Corticosteroids
  • Methylprednisolone given orally or intravenously, typically at 2 mg/kg/day in divided doses
  • Standard first-line treatment for moderate to severe acute skin GVHD
  • Median time to resolution is 30-42 days with steroid therapy
  • Gradually tapered to minimize side effects like infections, high blood sugar, and bone weakening
• Calcineurin Inhibitors
  • Cyclosporine and tacrolimus block immune cell activation signals
  • Used for GVHD prevention starting immediately after transplant
  • Continued during acute GVHD treatment, often combined with steroids
  • Tacrolimus frequently preferred for unrelated donor transplants due to better GVHD control
• Extracorporeal Photopheresis (ECP)
  • White blood cells collected, treated with light-sensitive medication and UV light, then returned to patient
  • Makes immune cells more susceptible to natural cell death, reducing immune attack
  • Used for both prevention and treatment of skin GVHD
  • Particularly considered for steroid-refractory cases
• Immunosuppressive Agents
  • Mycophenolate mofetil (MMF) interferes with immune cell production
  • Sirolimus blocks mTOR protein needed for immune cell multiplication
  • Often added when steroids aren’t adequately controlling GVHD
  • Used alone or in combination with other medications
• JAK Inhibitors (Clinical Trials)
  • Ruxolitinib and ibrutinib block Janus kinase enzymes that transmit inflammatory signals
  • Studied extensively in clinical trials for steroid-refractory GVHD
  • Show positive safety profiles and symptom improvements in some patients
  • Dampen immune response without complete immune system shutdown
• Monoclonal Antibodies (Clinical Trials)
  • Axatilimab (Niktimvo) blocks CSF-1 receptor on inflammatory macrophages
  • Rituximab targets CD20 protein on B lymphocytes
  • Anti-interleukin-2 receptor antibodies target activated immune cells
  • Designed to selectively reduce harmful immune activity
• ROCK2 Inhibitors (Clinical Trials)
  • Belumosudil (Rezurock) blocks Rho-associated coiled-coil kinase 2 enzyme
  • Affects multiple inflammatory pathways contributing to GVHD tissue damage
  • Evaluated in clinical trials in United States and Europe
  • Studied primarily for chronic GVHD but research continues
• Cell-Based Therapies (Clinical Trials)
  • Mesenchymal stem cell (MSC) infusions help regulate immune responses and promote tissue healing
  • Given as infusions from donors or laboratory-cultured cells
  • Early clinical trials show promise for steroid-refractory GVHD
  • More research needed to establish role in standard care
• Supportive Skin Care
  • Regular moisturizing with fragrance-free creams and lotions
  • Use of gentle, unperfumed soaps and warm (not hot) water
  • Wearing cotton clothing and avoiding extreme temperatures
  • Sun protection through covering up, shade, and sunscreen use
  • Gentle patting or air-drying rather than rubbing skin